Clinical usefulness of the branched DNA assay version 2 in predicting the efficacy of interferon treatment in a group of chronic HCV patients based on serotype

Sabina Mahmood, Kenichi Nakata, Miho Sho, Tomomi Kimura, Yuko Manabe, Shingo Kinoyama, Toshio Ito, Gotaro Yamada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Interferon (IFN) response depends upon pretreatment viral loads and viral genotype/serotype. This study investigated the difference in response to IFN in different viral load groups of 96 chronic hepatitis C patients and compared version 1 (bDNA 1.0) and version 2 (bDNA 2.0) of the branched DNA assay, according to serotype. On univariate analysis, viral load (P = 0.0001, by bDNA 1.0; P = 0.0020, by bDNA 2.0,), serotype (P = 0.0053) and age (P = 0.0073) were significant predictors of IFN response. On multivariate analysis, serotype (odds ratio, 5.44; 95% confidence interval, 1.94-15.24; P <0.01) was a stronger predictor of IFN response than age or viral load (by bDNA2.0). In very high (>6.7 log eq/ml), high (6.0 Ο 6.69 log eq/ml) and low ( <6 log eq/ml) viral load groups (by bDNA2.0), complete response was 25, 55 and 92.6% in serotype 2 (sero-2), and 10, 20 and 71.4% in serotype 1 (sero-1), respectively. In sero-2, bDNA2.0 can detect high viral loads underestimated by bDNA1.0. In a low viral load group (by bDNA2.0), IFN response is dependent upon serotype; sero-2 responded better than sero-1. However, in high and very high viral load groups, sensitivities of bDNA1.0 and bDNA2.0 are not effective in clinically distinguishing CR from non-response, and aid in patient selection for IFN therapy.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalHepatology Research
Volume20
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Branched DNA Signal Amplification Assay
Interferons
Viral Load
Serogroup
Chronic Hepatitis C
Patient Selection

Keywords

  • bDNA assay
  • Complete response
  • Interferon
  • Serotype
  • Viral load

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical usefulness of the branched DNA assay version 2 in predicting the efficacy of interferon treatment in a group of chronic HCV patients based on serotype. / Mahmood, Sabina; Nakata, Kenichi; Sho, Miho; Kimura, Tomomi; Manabe, Yuko; Kinoyama, Shingo; Ito, Toshio; Yamada, Gotaro.

In: Hepatology Research, Vol. 20, No. 1, 2001, p. 9-17.

Research output: Contribution to journalArticle

Mahmood, Sabina ; Nakata, Kenichi ; Sho, Miho ; Kimura, Tomomi ; Manabe, Yuko ; Kinoyama, Shingo ; Ito, Toshio ; Yamada, Gotaro. / Clinical usefulness of the branched DNA assay version 2 in predicting the efficacy of interferon treatment in a group of chronic HCV patients based on serotype. In: Hepatology Research. 2001 ; Vol. 20, No. 1. pp. 9-17.
@article{c1eb556e21344498a9ab50300a833bb4,
title = "Clinical usefulness of the branched DNA assay version 2 in predicting the efficacy of interferon treatment in a group of chronic HCV patients based on serotype",
abstract = "Interferon (IFN) response depends upon pretreatment viral loads and viral genotype/serotype. This study investigated the difference in response to IFN in different viral load groups of 96 chronic hepatitis C patients and compared version 1 (bDNA 1.0) and version 2 (bDNA 2.0) of the branched DNA assay, according to serotype. On univariate analysis, viral load (P = 0.0001, by bDNA 1.0; P = 0.0020, by bDNA 2.0,), serotype (P = 0.0053) and age (P = 0.0073) were significant predictors of IFN response. On multivariate analysis, serotype (odds ratio, 5.44; 95{\%} confidence interval, 1.94-15.24; P <0.01) was a stronger predictor of IFN response than age or viral load (by bDNA2.0). In very high (>6.7 log eq/ml), high (6.0 Ο 6.69 log eq/ml) and low ( <6 log eq/ml) viral load groups (by bDNA2.0), complete response was 25, 55 and 92.6{\%} in serotype 2 (sero-2), and 10, 20 and 71.4{\%} in serotype 1 (sero-1), respectively. In sero-2, bDNA2.0 can detect high viral loads underestimated by bDNA1.0. In a low viral load group (by bDNA2.0), IFN response is dependent upon serotype; sero-2 responded better than sero-1. However, in high and very high viral load groups, sensitivities of bDNA1.0 and bDNA2.0 are not effective in clinically distinguishing CR from non-response, and aid in patient selection for IFN therapy.",
keywords = "bDNA assay, Complete response, Interferon, Serotype, Viral load",
author = "Sabina Mahmood and Kenichi Nakata and Miho Sho and Tomomi Kimura and Yuko Manabe and Shingo Kinoyama and Toshio Ito and Gotaro Yamada",
year = "2001",
doi = "10.1016/S1386-6346(00)00118-2",
language = "English",
volume = "20",
pages = "9--17",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical usefulness of the branched DNA assay version 2 in predicting the efficacy of interferon treatment in a group of chronic HCV patients based on serotype

AU - Mahmood, Sabina

AU - Nakata, Kenichi

AU - Sho, Miho

AU - Kimura, Tomomi

AU - Manabe, Yuko

AU - Kinoyama, Shingo

AU - Ito, Toshio

AU - Yamada, Gotaro

PY - 2001

Y1 - 2001

N2 - Interferon (IFN) response depends upon pretreatment viral loads and viral genotype/serotype. This study investigated the difference in response to IFN in different viral load groups of 96 chronic hepatitis C patients and compared version 1 (bDNA 1.0) and version 2 (bDNA 2.0) of the branched DNA assay, according to serotype. On univariate analysis, viral load (P = 0.0001, by bDNA 1.0; P = 0.0020, by bDNA 2.0,), serotype (P = 0.0053) and age (P = 0.0073) were significant predictors of IFN response. On multivariate analysis, serotype (odds ratio, 5.44; 95% confidence interval, 1.94-15.24; P <0.01) was a stronger predictor of IFN response than age or viral load (by bDNA2.0). In very high (>6.7 log eq/ml), high (6.0 Ο 6.69 log eq/ml) and low ( <6 log eq/ml) viral load groups (by bDNA2.0), complete response was 25, 55 and 92.6% in serotype 2 (sero-2), and 10, 20 and 71.4% in serotype 1 (sero-1), respectively. In sero-2, bDNA2.0 can detect high viral loads underestimated by bDNA1.0. In a low viral load group (by bDNA2.0), IFN response is dependent upon serotype; sero-2 responded better than sero-1. However, in high and very high viral load groups, sensitivities of bDNA1.0 and bDNA2.0 are not effective in clinically distinguishing CR from non-response, and aid in patient selection for IFN therapy.

AB - Interferon (IFN) response depends upon pretreatment viral loads and viral genotype/serotype. This study investigated the difference in response to IFN in different viral load groups of 96 chronic hepatitis C patients and compared version 1 (bDNA 1.0) and version 2 (bDNA 2.0) of the branched DNA assay, according to serotype. On univariate analysis, viral load (P = 0.0001, by bDNA 1.0; P = 0.0020, by bDNA 2.0,), serotype (P = 0.0053) and age (P = 0.0073) were significant predictors of IFN response. On multivariate analysis, serotype (odds ratio, 5.44; 95% confidence interval, 1.94-15.24; P <0.01) was a stronger predictor of IFN response than age or viral load (by bDNA2.0). In very high (>6.7 log eq/ml), high (6.0 Ο 6.69 log eq/ml) and low ( <6 log eq/ml) viral load groups (by bDNA2.0), complete response was 25, 55 and 92.6% in serotype 2 (sero-2), and 10, 20 and 71.4% in serotype 1 (sero-1), respectively. In sero-2, bDNA2.0 can detect high viral loads underestimated by bDNA1.0. In a low viral load group (by bDNA2.0), IFN response is dependent upon serotype; sero-2 responded better than sero-1. However, in high and very high viral load groups, sensitivities of bDNA1.0 and bDNA2.0 are not effective in clinically distinguishing CR from non-response, and aid in patient selection for IFN therapy.

KW - bDNA assay

KW - Complete response

KW - Interferon

KW - Serotype

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0035067919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035067919&partnerID=8YFLogxK

U2 - 10.1016/S1386-6346(00)00118-2

DO - 10.1016/S1386-6346(00)00118-2

M3 - Article

AN - SCOPUS:0035067919

VL - 20

SP - 9

EP - 17

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 1

ER -